Miksödem Koması

Authors

Güner Yurtsever

Synopsis

Myxedema coma is a severe form of hypothyroidism characterized by worsening mental status, hypothermia, and multiorgan dysfunction, carrying a high mortality rate. Most commonly observed in elderly women, this condition can be triggered by the insidious course of chronic autoimmune thyroiditis, postoperative states, infections, myocardial infarction, surgical procedures, and the use of sedative drugs, particularly opioids. Clinical findings include lethargy, stupor, coma, psychotic presentations known as myxedema madness, seizures, edema of the face and hands, macroglossia, non-pitting edema, hyponatremia, hypoglycemia, respiratory depression, along with cardiovascular abnormalities such as bradycardia, hypotension, and pericardial effusion. In this emergency condition, which is a diagnosis of exclusion, serum T4 levels are generally low, while TSH is elevated in primary hypothyroidism and normal or low in central hypothyroidism; cortisol levels should also be measured due to the possibility of coexisting adrenal insufficiency. Upon clinical suspicion, treatment must be initiated immediately without waiting for laboratory results. Management requires a combination of intravenous T4 (levothyroxine) and T3 (liothyronine), as well as intravenous hydrocortisone at 100 mg every eight hours until adrenal insufficiency is ruled out. Supportive measures, including intensive care unit monitoring, mechanical ventilation support, passive rewarming with blankets, fluid-electrolyte balance, and empirical antibiotics, are of critical importance. With a mortality rate ranging between 30 and 50 percent, this condition must be managed aggressively.

References

Ono Y, Ono S, Yasunaga H, et al. Clinicalcharacteristicsandoutcomes of myxedemacoma: Analysis of a nationalinpatientdatabase in Japan. J Epidemiol 2017; 27:117.

Yafit D, Carmel-Neiderman NN, Levy N, et al. Postoperativemyxedemacoma in patients undergoingmajorsurgery: Case series. AurisNasusLarynx 2019; 46:605.

Kwaku MP, Burman KD. Myxedemacoma. J IntensiveCareMed 2007; 22:224.

Westphal SA. Unusualpresentations of hypothyroidism. Am J MedSci 1997; 314:333.

Mavroson MM, Patel N, Akker E. MyxedemaPsychosis in a PatientWithUndiagnosed HashimotoThyroiditis. J Am OsteopathAssoc 2017; 117:50.

Jansen HJ, Doebé SR, Louwerse ES, et al. Statusepilepticuscausedby a myxoedemacoma. Neth J Med 2006; 64:202.

Fjølner J, Søndergaard E, Kampmann U, Nielsen S. Complete recoveryafter severe myxoedemacomacomplicatedbystatusepilepticus. BMJ Case Rep 2015; 2015.

Iwasaki Y, Oiso Y, Yamauchi K, et al. Osmoregulation of plasmavasopressin in myxedema. J ClinEndocrinolMetab 1990; 70:534.

Shenoy MM, Goldman JM. Hypothyroidcardiomyopathy: echocardiographic documentation of reversibility. Am J MedSci 1987; 294:1.

HOLVEY DN, GOODNER CJ, NICOLOFF JT, DOWLING JT. TREATMENT OF MYXEDEMA COMA WITH INTRAVENOUS THYROXINE. ArchInternMed 1964; 113:89.

Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelinesforthetreatment of hypothyroidism: preparedbytheamericanthyroidassociationtaskforce on thyroidhormonereplacement. Thyroid 2014; 24:1670.

Yamamoto T, Fukuyama J, Fujiyoshi A. Factorsassociatedwithmortality of myxedema coma: report of eightcasesandliteraturesurvey. Thyroid 1999; 9:1167.

Zaninovich AA, el Tamer E, el Tamer S, et al. Multicompartmentalanalysis oftriiodothyroninekinetics in hypothyroidpatientstreatedorallyorintravenouslywithtriiodothyronine. Thyroid 1994; 4:285.29

Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedemacoma: a study from a tertiarycarecentre. CritCare 2008; 12:R1

Pages

77-84

Published

June 1, 2021

License

License